Search for: "PFIZER INC"
Results 1361 - 1380
of 1,505
Sorted by Relevance
|
Sort by Date
7 Feb 2008, 10:46 am
Medtronic, Inc., 231 F.3d 216, 230 (6th Cir. 2001).Kemp concluded that the purported "violations" before it were not violations at all - but merely reflected Plaintiffs' incorrect reading of FDA requirements. [read post]
22 Jan 2009, 2:06 am
Pfizer Inc., 358 F.3d 659, 661 (9th Cir. 2004) (same; physician considered warning inappropriate) (applying California law).Under these facts, if Conte were an ordinary prescription drug product liability case, plaintiff would have been out of court and out of luck, just like Motus. [read post]
29 Dec 2010, 12:54 pm
Wyeth, Inc. v. [read post]
8 Oct 2008, 11:50 am
Pfizer, Inc., 153 S.W.3d 758, 762 (Ky. 2004) (not a holding, but dictum suggesting broad comment k application).Louisiana: Kinney v. [read post]
17 May 2011, 10:37 pm
Align Technology, Inc., 463 F.3d 1299, 1311 (Fed. [read post]
28 Mar 2008, 6:00 am
: (Afro-IP),If education and pricing policy fail, says Adobe in Nigeria, we can still sue: (Afro-IP),South African arm of Chrysler objects to advertisement by Indian vehicle maker Mahindra and Mahindra that uses the term "jeep": (Afro-IP), (Spicy IP),Kenya’s call for anti-counterfeit legislation… amongst other changes: (Afro-IP),Kenya: Shared computer use raises privacy, confidentiality issues: (Afro-IP)AustraliaChanges to grace period for trade mark renewal:… [read post]
13 Apr 2014, 8:59 am
Pfizer Canada Inc., [2012] 3 S.C.R. 625 The patent system is based on a “bargain”, or quid pro quo: the inventor is granted exclusive rights in a new and useful invention for a limited period in exchange for disclosure of the invention so that society can benefit from this knowledge. [read post]
1 Dec 2017, 11:35 am
China’s Sanpower Group Co., Ltd. acquired Dendreon Pharmaceuticals Inc for $0.8 billion, and Sumitomo Dainippon Pharma Co., Ltd. acquired Tolero Pharmaceuticals Inc. for $0.8 billion to assist Sumitomo to refresh its pipeline.[28] In Q4 2017, a few M&A transactions have occurred in the pharma deal market. [read post]
23 Jan 2020, 10:37 pm
The phosphodiesterases 5 inhibitor medications (PDE5i) seem to arouse the litigation propensities of the lawsuit industry. [read post]
4 Jan 2010, 2:22 pm
Eric Affeldt, chief executive, ClubCorp Inc. [read post]
28 Apr 2011, 3:18 pm
By now Restatement (Second) of Torts §402A (1965) is so old as to be thought of as somewhat antediluvian. [read post]
19 Aug 2008, 10:35 pm
Vioxx came on the market in June 1999, after rival Pfizer Inc.'s Celebrex. [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
30 Sep 2011, 3:14 am
[Link] Dynamics Inc. is seeking a patent attorney with an EE degree, to work at their Pittsburgh location. [read post]
20 Jul 2011, 4:04 am
(Spicy IP) US: Multicell Technologies receives stem cell patent (Patent Docs) US: FDA’s NDI guidance and the 18-year cycle of correcting regulatory overreach (FDA Law Blog) Products Adenoscan (Adenosine) – US: Astellas settles Adenoscan patent suit with Sagent and Strides Arcolab (Patent Docs) Angiomax (Bivalirudin) – US: The MDCO PTE decision: In play on Capitol Hill and in action at the PTO (FDA Law Blog) Cipralex (Escitalopram) – Austria: SPCs and Escitalopram in… [read post]
28 Oct 2011, 10:06 am
The Moderator: Ronald Staudt, IIT Chicago-Kent College of Law The Panelists: Toby Brown, Vinson & Elkins; Lisa Damon, Seyfarth Shaw LLP; Paul Lippe, Legal OnRamp; Mark Ohringer, Jones Lang LaSalle Americas, Inc.; and Ellen Rosenthal, Pfizer Lisa Damon, Seyfarth Shaw LLP Seyfarth Lean Background: About 6 years ago, clients started asking for alternative fees. [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
11 Nov 2009, 8:10 am
New London remain vacant, but that Pfizer, Inc. [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
1 Feb 2024, 9:39 am
Typically, they earn a salary far less than their brethren at Merck, Pfizer, IBM or DuPont. [read post]
